Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Date:1/3/2008

ASHBURN, Va., Jan. 2 /PRNewswire/ -- Innocoll, Inc., a privately-held specialty pharmaceutical company, announced that the first of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the prevention of surgical site infections, has commenced dosing.

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the US) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues. GENTAMICIN SURGICAL IMPLANT is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totalling over 7,500 patients documenting its safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures.

Following a pre-IND meeting with the FDA earlier this year, Innocoll will conduct two multi-centered phase 3 clinical trials in the US to support the planned New Drug Application (NDA); the first in cardiac surgery patients at higher risk of surgical site infection and the second, expected to start later this month, in patients undergoing open colorectal surgery, which is considered to be the category most prone to surgical site infection. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Today, DripDrop, ... announced the formation of the DripDrop Foundation, with ... preventable dehydration worldwide. Utilizing scientific advancements in Oral ... solutions to reduce dehydration and healthcare costs through ... missions. "DripDrop has been used ...
(Date:9/23/2014)... Wash. , Sept. 23, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... two new additions to its Scientific Advisory Board.  The ... Anthony Davies , PhD. Dr. Acker ...
(Date:9/22/2014)... -- , La tecnología basada en ... satisfagan el creciente rigor de las autoridades sanitarias en ... permanentes de ensayo (TMF, por sus siglas en inglés) ... el sector de las ciencias biológicas hasta la fecha ... ensayos clínicos que planean proporcionar a los auditores acceso ...
Breaking Medicine Technology:DripDrop Forms Foundation To Scale Relief Efforts 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5
... April 19, 2011 Genetic Technologies Limited ... preliminary research collaboration agreement to jointly develop a new ... pharmaceutical companies. Under the collaboration Genetic ... work with this world-leading pharmaceutical company to develop specific ...
... April 19, 2011 If your medicine has expired, ... this Consumer Update video, FDA pharmacist Ilisa Bernstein explains ... to use and will work as intended. ... http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm251658.htm Sign up for e-mail notices ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:9/23/2014)... September 23, 2014 Wellesley, Mass., September ... in its new report, Joint Reconstruction and ... market for joint reconstruction and replacement is expected to ... compound annual growth rate (CAGR) of 4.2% from 2013 ... the major regions, surging at a CAGR of 5.1%. ...
(Date:9/23/2014)... 2014 Given the nondiscretionary nature ... Fruit and Vegetable Markets industry is generally ... benefited operators over the five years to 2014. ... and demographic trends, including a focus on healthy ... capita fruit and vegetable consumption declined at an ...
(Date:9/23/2014)... "area under the curve of oxygen desaturation" (AUC Desat ... blood oxygen levels during procedures using sedation, according to ... , The AUC Desat provides information not only ... the depth, duration, and rate of episodes of oxygen ... of University of Cincinnati and colleagues reports on the ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
(Date:9/23/2014)... NEW YORK, NY (PRWEB) September 23, 2014 ... the best innovators in the pharmaceutical industry with their ... honors, bestowed at a gala banquet at Gotham Hall ... marketers and brand managers representing top talent and brands. ... to celebrate its accomplishments,” says Anna Stashower, CEO and ...
Breaking Medicine News(10 mins):Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New hope for beloved family pets 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6
... POTOMAC FALLS, Va., Nov. 3 "When my father ... read every book,pamphlet, and newspaper article I could get ... book, "A Conversation About Alzheimer,s" (published by,AuthorHouse -- ... think about. I told myself that once I knew ...
... more common for adolescents illegally at the wheel, study finds, ... the thought of teenagers driving before they,ve gotten their license ... are also more likely to drive while drinking or on ... get behind the wheel. , Reporting in the November issue ...
... JOHNSON,S(R) Partners With MARCH OF DIMES(R) To Build ... The United States, SKILLMAN, N.J., Nov. 3 ... of "Prematurity Awareness Month" that partners,with the March ... growing problem of,premature birth and raise funds to ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (Nasdaq: CHBT ) ... the research, development, manufacture, marketing and,distribution of probiotics ... call at 9:00 a.m. EST on Tuesday, November ... the second quarter ended,September 30, 2008, of its ...
... Nov. 3 Hooper Holmes,(Amex: HH ) today ... before market on Friday, November 7, 2008. The Company,will ... at 11:00am Eastern,Time., Conference Call, To participate ... code: Hooper Holmes. A live web cast will be ...
... Inc. (Nasdaq: MBRK ), a pharmaceutical ... products, today,announced that it has retained national ... will serve as MiddleBrook,s strategic and tactical ... reimbursement, contract,administration, national account management and government ...
Cached Medicine News:Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Many Unlicensed Teen Drivers Put Safety Last 2Health News:Many Unlicensed Teen Drivers Put Safety Last 3Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 2Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 3Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 3Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
... of rubella IgG antibody in women prior ... from possible rubella viral infection during pregnancy. ... greatly reduced the incidence of rubella epidemics, ... monitoring of immune status, especially for women ...
... IgG antibody in women prior to conception ... rubella viral infection during pregnancy. Aggressive ... the incidence of rubella epidemics, but a ... immune status, especially for women of child-bearing ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
Medicine Products: